|
Entire cohort
(n=140)
|
N group
(n=23)
|
Y group
(n=117)
|
p value
|
Age (years) |
84.6±5.4 |
92.1±1.9 |
83.2±4.7 |
<0.0001 |
[range] |
[69-97] |
[90–97] |
[69–89] |
|
Male |
47 (33.5%) |
5 (21.7%) |
42 (35.8%) |
0.18 |
Hypertension |
126 (90.0%) |
22 (95.6%) |
104 (88.8%) |
0.32 |
Dyslipidemia |
77 (55%) |
12 (52.1%) |
65 (55.5%) |
0.76 |
DM |
38 (27.1%) |
4 (17.3%) |
34 (29.0%) |
0.25 |
IHD |
55 (39.2%) |
4 (17.3%) |
51 (43.5%) |
0.13 |
CVD |
36 (25.7%) |
4 (17.3%) |
32 (27.3%) |
0.30 |
COPD |
6 (4.2%) |
0 |
6 (5.1%) |
0.58 |
Smoking |
9 (6.4%) |
0 |
9 (7.6%) |
0.35 |
Chronic AF |
21 (15.0%) |
4 (17.3%) |
17 (14.5%) |
0.72 |
PMI |
11 (7.8%) |
4 (17.3%) |
7 (5.9%) |
0.09 |
Malignancy |
7 (5.0%) |
1 (4.3%) |
6 (5.1%) |
0.98 |
Previous cardiac surgery |
11 (7.8%) |
1 (4.3%) |
10 (8.5%) |
0.49 |
Serum creatinine (mg/dl) |
1.01±0.31 |
0.98±0.29 |
1.02±0.29 |
0.60 |
Serum albumin (g/dl) |
3.66±0.40 |
3.74±0.38 |
3.64±0.40 |
0.27 |
Hemoglobin (g/dl) |
10.80±1.68 |
10.34±1.53 |
10.89±1.70 |
0.15 |
Oral administration |
|
|
|
|
β-blocker |
22 (15.7%) |
5 (21.7%) |
41 (35.0%) |
0.26 |
Ca2+ blocker |
67 (47.8%) |
13 (56.5%) |
54 (46.1%) |
0.36 |
ACE-I |
34 (24.2%) |
5 (21.7%) |
29 (24.7%) |
0.75 |
ARB |
57 (40.7%) |
13 (56.5%) |
44 (37.6%) |
0.09 |
Statins |
62 (44.2%) |
10 (43.4%) |
52 (44.4%) |
0.93 |
Risk score |
|
|
|
|
STS risk score |
7.9±4.6 |
8.4±4.6 |
7.7±4.8 |
0.50 |
EuroSCORE II |
5.1±4.7 |
5.4±3.3 |
5.0±4.9 |
0.72 |
JapanSCORE |
7.2±6.2 |
5.1±4.7 |
7.6±6.8 |
0.09 |